

**MHIF FEATURED STUDY:**  
**WARRIOR - Women's Ischemia Trial**

**OPEN AND ENROLLING:**  
EPIC message: *Research MHIF Patient Referral*

<b>CONDITION:</b> Non-Obstructive CAD in Women	<b>PI:</b> Retu Saxena, MD	<b>RESEARCH CONTACT:</b> Steph Ebnet <a href="mailto:Stephanie.ebnet@allina.com">Stephanie.ebnet@allina.com</a>   612-863-6286	<b>SPONSOR:</b> University of FL Funded by the Department of Defense
---	-------------------------------	---	---

**DESCRIPTION:**

The purpose of WARRIOR (Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD) is to evaluate if intensive medical therapy (IMT) (**potent statin plus ACE-I or ARB**) is better than usual care in women who have s/s of suspected ischemia but no obstructive CAD (defined as <50 stenosis). The hypothesis is that IMT will reduce MACE 20% vs. usual care.

**CRITERIA LIST/ QUALIFICATIONS:**

**Inclusion**

- Signs and symptoms of suspected ischemia prompting referral for further evaluation by coronary angiography or coronary CT angiogram within previous 3 years
- Non-obstructive CAD defined as 0-50% diameter reduction of a major epicardial vessel

**Exclusion**

- Hx NIHCM
- ACS within 30 days
- LVEF < 40% NYHA HF class III-IV
- Prior intolerance to ACE/ARB
- ESRD on dialysis
- Severe valvular disease requiring TVAR within 3 years
- Stroke within 180 days





Are you a **woman** who within the last **five years** has had chest pain severe enough to be evaluated by either:

- A CT scan of your heart
- A cardiac catheterization

And the finding indicated **no significant** coronary artery blockages?

**WARRIOR**



Women who experience chest pain and other signs of ischemia who are evaluated and found to have no significant blockages in their coronary arteries are often released from cardiac care, labeled normal, but continue to have symptoms.

WARRIOR is a clinical trial designed to determine how to best treat women with chest pain and no significant coronary artery disease.

**PI:**  
Retu Saxena, MD

**RESEARCH CONTACT:**  
Steph Ebnet, RN

[Stephanie.ebnet@allina.com](mailto:Stephanie.ebnet@allina.com) | [612-863-6286](tel:612-863-6286)

**HOPE**  
DISCOVERED HERE™

 **Minneapolis  
Heart Institute  
Foundation**  
Creating a world without heart and vascular disease

# Adjuncts during F-BEVAR: upper extremity access and future directions

Aleem K Mirza, MD

*From the Division of Vascular and Endovascular Surgery  
Minneapolis Heart Institute Foundation*



Allina Health  
ABBOTT  
NORTHWESTERN  
HOSPITAL

## Disclosures


- No financial disclosures
- Cases and images courtesy of Gustavo Oderich, Mayo Clinic





## Overview

- History of fenestrated-branched technology
- Overview on adjuncts during F-BEVAR
  - Preloaded systems
  - Upper extremity access
  - Total femoral approach
- Case presentations
- Current research

## Evolution of fen-branched repair



*In Oderich Atlas of Fenestrated, Branched and Parallel Techniques, Springer 2016*



## Emergency use of physician-modified fenestrated endograft for symptomatic post-dissection thoracoabdominal aneurysm waiting for a manufactured endograft

Aleem K Mirza, Jussi M Kärkkäinen, Emanuel R Tenorio, Nishant Saran, Gustavo S Oderich

### Disclosures



GSO: consulting and research grants paid to Mayo Clinic (Cook, WL Gore, GE Healthcare)

Other authors: nothing to disclose

## 59-year old female with 7cm Extent II TAAA


- Prior arch repair with elephant trunk technique
- Cardiovascular risk factors
  - Hypertension, hyperlipidemia, CAD, COPD, prior smoking
- Planned staged TAAA repair
  - Stage I: TEVAR with angioplasty of small R renal reentrance
  - Stage II: patient-specific manufactured fenestrated and branched endograft





## Operative technique – stage II

- 4 – vessel fenestrated completion PMEG repair
- Preloaded wires from left brachial approach
- Distal extension with a bifurcated device



## Postoperative course


- ICU cares for 4 days
- Day 1 – spinal drain removed
- Day 2 – replaced x 24 hrs for lower extremity weakness
- Day 10 – hospital discharge
- Neurologically intact
- Creatinine 1.1-mg/dL



## 65-year-old male with rapid aneurysm sac growth after 4-vessel branched endovascular aortic repair


Aleem K. Mirza MD  
Swati Chaparala MD  
Bernardo C. Mendes MD  
Gustavo S. Oderich MD

From the Aortic Endovascular Research Program  
Division of Vascular and Endovascular Surgery



## History of present illness

- 65M with persistent aneurysm sac growth
  - Prior 4-vessel PMEG for ruptured Extent III TAAA in 2015
  - Rapid growth of 8-mm in 7 months
  - No fevers, chills, night sweats
- New thoracic back pain
- Past medical history
  - Open infrarenal AAA repair
  - Multiple sclerosis with chronic debility
  - COPD on nocturnal O<sub>2</sub>
  - Chronic thrombocytopenia




## Physical exam



- General: **tachypnea on 4L nasal cannula**
- Cardiac: regular rate, no murmurs
- Pulmonary: **bibasilar crackles**
- Abdomen: soft, nontender, no pulsatile mass
- Extremities: **2+ pitting edema**
- Vessels:



	Radial	Carotid	Femoral	DP	PT
Right:	+	+	+	(+)	(+)
Left:	+	+	+	(+)	(+)



## Preoperative evaluation

- Creatinine: 0.6 mg/dL
- Platelets: 52,000
- Echocardiogram: EF 61%
- Indium-labeled WBC scan: no infection











## Operative – plan



- 4-vessel  
PMEG
- 3 inner  
branches
- 1 fenestration

## ALPHA THORACIC LP (18-20Fr)




- Select smaller tapered stent in larger sheath
- Un-sheath entire stent but keep metallic cannula




## Postoperative course



- ICU cares x 16 days
  - Respiratory support
  - Tracheostomy on POD 17
- No new neurologic deficits
- Dismissed on POD 31
- ASA 81mg, Plavix 75mg


## Imaging summary



## Platelet trend







**Outcomes of upper extremity access during fenestrated-branched endovascular aortic repair**

**PRESENTED BY:**  
Aleem K. Mirza MD, Gustavo S. Oderich MD, Giuliano Sandri MD, Emanuel Tenorio MD PhD, Victor J. Davila MD, Jan Hofer RN, Jean Wigham RN and Stephan Cha MS

Mayo Clinic, Rochester MN

Disclosures  
GSO: consulting and research grants paid to Mayo Clinic (Cook, WL Gore, GE Healthcare)  
Other authors: nothing to disclose




## Background

- Fenestrated-branched endovascular aortic repair (F-BEVAR) has been widely used for complex aneurysm repair
- Upper extremity (UE) access is often needed for catheterization of caudally-oriented vessels or directional branches
- Limitations are the risks of cerebral embolization, upper extremity arterial and peripheral nerve injury

## Purpose

- The aim of this study was to evaluate the outcomes of F-BEVAR using UE access with small and large sheaths



## Methods

- Retrospective review of a prospectively collected database
- Included patients treated by F-BEVAR for thoracoabdominal (TAAA) or pararenal aortic aneurysms (PAA) using UE access
- Endpoints:
  - Mortality and Major Adverse Events (MAEs)
  - Access-related complications


## Access-related complications

- Any stroke or TIA
- UE arterial complication resulting in symptoms, disability or reintervention: hematoma, pseudoaneurysm, dissection, stenosis, thrombosis or distal embolization
- Peripheral nerve injury
- UE wound-related complication: seroma, lymphatic leak or infection

## Patients


**334 patients treated by F-BEVAR (2007-2016)**

Included 243 patients (73%) who had F-BEVAR with UE access




## Selection of access site



- Left side selected whenever possible



## Access technique

- All patients had surgical exposure





## UE arterial closure

- 212 patients (87%) had primary closure
- 30 patients (12%) had Bovine patch angioplasty
- 1 patient (0.4%) had vein interposition graft

Indication	Total (n = 243)	Pararenal (n = 96)	Extent IV (n = 69)	Extent I-III (n = 78)	P value
Total	31 (13)	9 (9)	7 (10)	15 (19)	0.13
Dissection	29 (12)	9 (9)	7 (10)	13 (17)	0.28
Thrombosis	1 (0.4)	0	0	1 (1)	0.32
Transection	1 (0.4)	0	0	1 (1)	0.32

## Access-related complications

8 patients (3%) had access-related complications

Complication	Total (n = 243)	Pararenal (n = 96)	Extent IV (n = 69)	Extent I-III (n = 78)	P value
Stroke	5 (2)	2 (2)	2 (3)	1(1)	0.8
Neuropraxia	2 (1)	2 (2)	0	0	0.24
Hematoma*	1 (0.4)	1 (0)	0	0	1

- No pseudoaneurysm, stenosis, thrombosis, distal embolization or UE wound infection
- No loss of UE arterial patency after mean follow up of 38±15 months

\* Hematoma requiring surgical evacuation

## Cerebral events


5 patients (2%) had stroke

Complication	Total (n = 243)	Pararenal (n = 96)	Extent IV (n = 69)		Extent I-III (n = 78)	P value
			n (%)			
Minor stroke	3 (1)	0	1 (1)		2 (3)	0.27
Major stroke	2 (1)	1 (1)	0		1 (1)	0.65

- 2 patients (1%) had asymptomatic cerebral emboli incidentally diagnosed by imaging studies
- Right UE access was associated with more strokes compared to left UE access (13% vs 1%, P=0.03)

## Conclusions

- Upper extremity arterial access using surgical exposure and large diameter sheaths was associated with low rates of complications, stroke and peripheral nerve injuries in patients treated by F-BEVAR
- Left-sided UE access was associated with lower stroke rates



Radiation physics

Minimizing radiation exposure to the vascular surgeon

Surgeon radiation dose during complex endovascular procedures


M.R. Radiation exposure to operating room personnel and patients during endovascular procedures

Abhisekh Mohapatra, BA,<sup>a</sup> Roy K. Greenberg, MD,<sup>b</sup> Tara M. Mastracci, MD,<sup>b</sup> Matthew J. Eagleton, MD,<sup>b</sup> and Brett Thornsberry, RT(R),<sup>b</sup> *Cleveland, Ohio*

# CEREBROEMBOLIC OUTCOMES OF RIGHT VS LEFT UPPER EXTREMITY ACCESS DURING F-BEVAR

Aleem K. Mirza, Emanuel R. Tenorio, Jussi M. Kärkkäinen, and Gustavo S. Oderich

Advanced Endovascular Aortic Program  
Mayo Clinic Aortic Center, *Rochester Minnesota*




International Symposium CHARING CROSS 15-18 APRIL 2019 MONDAY-THURSDAY OLYMPIA LONDON • UNITED KINGDOM

MAYO CLINIC

## Purpose


- The aim of this study was to evaluate cerebroembolic outcomes of right (RUE) versus left (LUE) upper extremity access for F-BEVAR



## Methods

- Retrospective review of a prospectively collected database, under a physician-sponsored investigational device exemption
- All consecutive patients treated by F-BEVAR for thoracoabdominal (TAAA) and pararenal aneurysms (PRA) between 2013 and 2018
  - Included patients with UE with 12F sheaths
- Primary endpoints:
  - Major adverse events, mortality, technical success





	Arch type	Thrombus type	Thickness	Area	Circumference	
0 points						
Mild: 0-3						
Moderate: 4-7						
Severe: 8-10						
2 points						
Maximum	2	2	2	2	2	10

## Target-vessel incorporation

Technical success was 99% (202/205) for LUE and 92% (60/65) for RUE access, P=0.02

	Total (n = 270)	LUE access (n = 205)	RUE access (n = 65)	P value
<i>Percent or Mean ± Standard Deviation</i>				
Total vessels incorporated	1054	804	250	NA
No. vessels per patient	3.9±0.6	3.9±0.5	3.8±0.7	0.21
Total vessels via UE access	689 (65)	523 (65)	166 (66)	0.75
No. vessels via UE per patient	2.6±1.0	2.6±0.9	2.6±1.0	0.88
Preloaded system	195 (72)	147 (72)	48 (74)	0.87



## Major adverse events

	Total (n = 270)	LUE access (n = 205)	RUE access (n = 65)	P value
<i>Percent or Mean ± Standard Deviation</i>				
Death	2 (1)	1 (1)	1 (1)	0.42
Any MAE	82 (30)	65 (32)	17 (26)	0.44
Acute kidney injury	39 (14)	28 (14)	11 (17)	0.54
Estimated blood loss >1L	30 (11)	24 (12)	6 (9)	0.66
Myocardial infarction	10 (4)	8 (4)	2 (3)	1.00
SCI grade 3a – c	8 (3)	6 (3)	2 (3)	1.00
Stroke	7 (3)	6 (3)	1 (2)	1.00
Respiratory failure	6 (2)	4 (2)	2 (3)	0.63
Bowel ischemia	24 (9)	18 (9)	6 (9)	1.00

- Mean follow-up was 19 ± 14 months



## Embololic stroke

	Total (n = 270)	LUE access (n = 205)	RUE access (n = 65)	P value
<i>Percent or Mean ± Standard Deviation</i>				
Embololic stroke	5 (2)	4 (2)	1 (1.5)	0.65
Ipsilateral stroke	4 (2)	3 (1.5)	1 (1.5)	0.67
Minor stroke	3 (1)	3 (2)	0	0.43
Major stroke	2 (0.5)	1 (0.5)	1 (1.5)	0.42
Posterior circulation	3 (1)	2 (1)	1 (1.5)	0.56
Anterior circulation	1 (0.5)	1 (0.5)	0	0.76
Combined ant. & post.	1 (0.5)	1 (0.5)	0	0.76

- Five patients had embolic strokes
- Four patients had strokes ipsilateral access to UE access



## Embololic stroke

Points	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
<b>Total score</b>	<b>4</b>	<b>4</b>	<b>5</b>	<b>5</b>	<b>7</b>
Arch type	2	2	2	1	2
Thrombus type	1	1	1	1	2
Thrombus thickness	1	1	1	1	2
Thrombus area	0	0	0	0	0
Thrombus circumference	0	0	1	2	1


- Four strokes (80%) had type III arches
- One stroke (20%) had a type II arch

Mild: 0-3  
 Moderate: 4-7  
 Severe: 8-10



## Conclusions

- Right and left UE access during F-BEVAR have similar rate of cerebroembolic complications and procedural metrics
  - Radiation dose was lower with right UE access
- The majority of strokes occurred with unfavorable type III aortic arches



78-year-old man with enlarging Extent II TAAA after DeBakey Type I aortic dissection, prior ascending aortic repair and EVAR

Aleem Mirza MD and Gustavo S. Oderich MD

From the Aortic Endovascular Research Program  
Division of Vascular and Endovascular Surgery



## Current research


### Anatomic characteristics of the aortic arch associated with cerebroembolism

- Aims:
  - evaluate the incidence of stroke after TEVAR and TAVR
  - Determine anatomic characteristics of the aortic arch that predispose to stroke

## Current research

### Anatomic characteristics of the aortic arch associated with cerebroembolism

- Patients:
  - >1000 patients who underwent TEVAR/TAVR
  - Exclude those with cerebral protection
- Preoperative CTA
  - Centerline-flow imaging



## References

1. Mirza AK, Oderich GS, Sandri GA, et al. Outcomes of upper extremity access during fenestrated-branched endovascular aortic repair. *J Vasc Surg.* 2019;69(3):635–643.
2. D’Oria M, Mirza AK, Tenorio ER, Kärkkäinen JM, DeMartino RR, Oderich GS. Physician-Modified Endograft With Double Inner Branches for Urgent Repair of Supraceliac Para-Anastomotic Pseudoaneurysm. *J Endovasc Ther.* 2020;27(1):124–129. doi:10.1177/1526602819890108
3. Mirza AK, Tenorio ER, Kärkkäinen JM, Ozbek P, Oderich GS. Technical video of endovascular repair of chronic postdissection thoracoabdominal aortic aneurysm using a five-vessel preloaded fenestrated-branched stent graft. *J Vasc Surg.* 2019;69(1):296–302.e1. doi:10.1016/j.jvs.2018.09.042
4. Tenorio ER, Mirza AK, Kärkkäinen JM, Oderich GS. Lessons learned and learning curve of fenestrated and branched endografts. *J Cardiovasc Surg (Torino).* 2019;60(1):23–34. doi:10.23736/S0021-9509.18.10728-2
5. Mohapatra A, Greenberg RK, Mastracci TM, Eagleton MJ, Thornsberry B. Radiation exposure to operating room personnel and patients during endovascular procedures. *J Vasc Surg.* 2013;58(3):702–709. doi:10.1016/j.jvs.2013.02.032
6. Kirkwood ML, Guild JB, Arbique GM, Anderson JA, Valentine RJ, Timaran C. Surgeon radiation dose during complex endovascular procedures. *J Vasc Surg.* 2015;62(2):457–463. doi:10.1016/j.jvs.2015.02.050
7. Mirza AK, Tenorio ER, Kärkkäinen JM, et al. Outcomes of a novel upper extremity preloaded delivery system for fenestrated-branched endovascular repair of thoracoabdominal aneurysms [published online ahead of print, 2020 Jan 24]. *J Vasc Surg.* 2020;S0741-5214(19)32577-7. doi:10.1016/j.jvs.2019.09.058

*From the Division of Vascular and Endovascular Surgery  
Minneapolis Heart Institute Foundation*



MINNEAPOLIS  
HEART  
INSTITUTE

Allina Health  
ABBOTT  
NORTHWESTERN  
HOSPITAL